Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development

Cancer Cell

Volumn 30, Issue 1, 2016, Pages 92-107

  Lu, Rui ^a   Wang, Ping ^b   Parton, Trevor ^a   Zhou, Yang ^a   Chrysovergis, Kaliopi ^c   Rockowitz, Shira ^b   Chen, Wei Yi ^d   Abdel Wahab, Omar ^e   Wade, Paul A ^c   Zheng, Deyou ^b   Wang, Gang Greg ^a,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DNA METHYLTRANSFERASE 3A; DNA (CYTOSINE 5) METHYLTRANSFERASE; HOMEODOMAIN PROTEIN; METHYLTRANSFERASE; MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; TUMOR PROTEIN;

ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; CPG ISLAND; CRISPR CAS SYSTEM; DNA METHYLATION; DNMT3A GENE; ENHANCER REGION; EPIGENETICS; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HISTONE MODIFICATION; HOXA GENE; LEUKEMOGENESIS; MEIS1 GENE; MN1 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; TRANSACTIVATION; ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; EXPERIMENTAL NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MUTATION; ONCOGENE RAS; PATHOLOGY; PROMOTER REGION; STEM CELL; TUMOR CELL CULTURE;

ANIMALS; ARGININE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, RAS; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; METHYLTRANSFERASES; MICE; MUTATION; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS, GENETIC; STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84979781455     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.05.008     Document Type: Article

References (45)

1. Abramovich, C., Pineault, N., Ohta, H., Humphries, R.K., Hox genes: from leukemia to hematopoietic stem cell expansion. Ann. N. Y. Acad. Sci. 1044 (2005), 109–116.
2. Argiropoulos, B., Humphries, R.K., Hox genes in hematopoiesis and leukemogenesis. Oncogene 26 (2007), 6766–6776.
3. Baubec, T., Schubeler, D., Genomic patterns and context specific interpretation of DNA methylation. Curr. Opin. Genet. Dev. 25 (2014), 85–92.
4. Bernt, K.M., Zhu, N., Sinha, A.U., Vempati, S., Faber, J., Krivtsov, A.V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20 (2011), 66–78.
5. Campisi, J., d'Adda di Fagagna, F., Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8 (2007), 729–740.
6. Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368 (2013), 2059–2074.
7. Celik, H., Mallaney, C., Kothari, A., Ostrander, E.L., Eultgen, E., Martens, A., Miller, C.A., Hundal, J., Klco, J.M., Challen, G.A., Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 125 (2015), 619–628.
8. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44 (2012), 23–31.
9. Chang, Y.I., You, X., Kong, G., Ranheim, E.A., Wang, J., Du, J., Liu, Y., Zhou, Y., Ryu, M.J., Zhang, J., Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia 29 (2015), 1847–1856.
10. Chen, C.W., Koche, R.P., Sinha, A.U., Deshpande, A.J., Zhu, N., Eng, R., Doench, J.G., Xu, H., Chu, S.H., Qi, J., et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21 (2015), 335–343.
11. Chi, P., Allis, C.D., Wang, G.G., Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10 (2010), 457–469.
12. Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17 (2011), 1086–1093.
13. Genovese, G., Kahler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371 (2014), 2477–2487.
14. Guo, X., Wang, L., Li, J., Ding, Z., Xiao, J., Yin, X., He, S., Shi, P., Dong, L., Li, G., et al. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature 517 (2015), 640–644.
15. Heuser, M., Yun, H., Berg, T., Yung, E., Argiropoulos, B., Kuchenbauer, F., Park, G., Hamwi, I., Palmqvist, L., Lai, C.K., et al. Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell 20 (2011), 39–52.
16. Holz-Schietinger, C., Matje, D.M., Reich, N.O., Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J. Biol. Chem. 287 (2012), 30941–30951.
17. Huang, Y., Sitwala, K., Bronstein, J., Sanders, D., Dandekar, M., Collins, C., Robertson, G., MacDonald, J., Cezard, T., Bilenky, M., et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 119 (2012), 388–398.
18. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burtt, N., Chavez, A., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371 (2014), 2488–2498.
19. Jones, P.A., Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13 (2012), 484–492.
20. Kim, S.J., Zhao, H., Hardikar, S., Singh, A.K., Goodell, M.A., Chen, T., A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122 (2013), 4086–4089.
21. Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber, J., Levine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006), 818–822.
22. Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., Zaretsky, I., Jaitin, D.A., David, E., Keren-Shaul, H., Mildner, A., Winter, D., Jung, S., et al. Immunogenetics. Chromatin state dynamics during blood formation. Science 345 (2014), 943–949.
23. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363 (2010), 2424–2433.
24. Li, Y., Wen, H., Xi, Y., Tanaka, K., Wang, H., Peng, D., Ren, Y., Jin, Q., Dent, S.Y., Li, W., et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159 (2014), 558–571.
25. Mayle, A., Yang, L., Rodriguez, B., Zhou, T., Chang, E., Curry, C.V., Challen, G.A., Li, W., Wheeler, D., Rebel, V.I., Goodell, M.A., Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 125 (2015), 629–638.
26. Noh, K.M., Wang, H., Kim, H.R., Wenderski, W., Fang, F., Li, C.H., Dewell, S., Hughes, S.H., Melnick, A.M., Patel, D.J., et al. Engineering of a histone-recognition domain in Dnmt3a alters the epigenetic landscape and phenotypic features of mouse ESCs. Mol. Cell 59 (2015), 89–103.
27. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366 (2012), 1079–1089.
28. Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., Wysocka, J., A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470 (2011), 279–283.
29. Russler-Germain, D.A., Spencer, D.H., Young, M.A., Lamprecht, T.L., Miller, C.A., Fulton, R., Meyer, M.R., Erdmann-Gilmore, P., Townsend, R.R., Wilson, R.K., Ley, T.J., The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25 (2014), 442–454.
30. Schmidl, C., Klug, M., Boeld, T.J., Andreesen, R., Hoffmann, P., Edinger, M., Rehli, M., Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 19 (2009), 1165–1174.
31. Schubeler, D., Function and information content of DNA methylation. Nature 517 (2015), 321–326.
32. Shih, A.H., Abdel-Wahab, O., Patel, J.P., Levine, R.L., The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12 (2012), 599–612.
33. Shih, A.H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27 (2015), 502–515.
34. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506 (2014), 328–333.
35. Wang, G.G., Pasillas, M.P., Kamps, M.P., Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood 106 (2005), 254–264.
36. Wang, G.G., Pasillas, M.P., Kamps, M.P., Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. Mol. Cell Biol. 26 (2006), 3902–3916.
37. Wang, G.G., Cai, L., Pasillas, M.P., Kamps, M.P., NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9 (2007), 804–812.
38. Wang, G.G., Song, J., Wang, Z., Dormann, H.L., Casadio, F., Li, H., Luo, J.L., Patel, D.J., Allis, C.D., Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 459 (2009), 847–851.
39. Wong, P., Iwasaki, M., Somervaille, T.C., So, C.W., Cleary, M.L., Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 21 (2007), 2762–2774.
40. Xiang, P., Wei, W., Lo, C., Rosten, P., Hou, J., Hoodless, P.A., Bilenky, M., Bonifer, C., Cockerill, P.N., Kirkpatrick, A., et al. Delineating MEIS1 cis-regulatory elements active in hematopoietic cells. Leukemia 28 (2014), 433–436.
41. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20 (2014), 1472–1478.
42. Xu, J., Wang, Y.Y., Dai, Y.J., Zhang, W., Zhang, W.N., Xiong, S.M., Gu, Z.H., Wang, K.K., Zeng, R., Chen, Z., Chen, S.J., DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc. Natl. Acad. Sci. USA 111 (2014), 2620–2625.
43. Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43 (2011), 309–315.
44. Yang, L., Rau, R., Goodell, M.A., DNMT3A in haematological malignancies. Nat. Rev. Cancer 15 (2015), 152–165.
45. Zhang, J., Wang, J., Liu, Y., Sidik, H., Young, K.H., Lodish, H.F., Fleming, M.D., Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113 (2009), 1304–1314.